Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.
2.

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.

Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, Notcutt W, O'Leary C, Ratcliffe S, Nováková I, Zapletalova O, Piková J, Ambler Z.

Neurol Res. 2010 Jun;32(5):451-9. doi: 10.1179/016164109X12590518685660.

PMID:
20307378
3.
5.

Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.

Lu L, Pearce H, Roome C, Shearer J, Lang IA, Stein K.

Pharmacoeconomics. 2012 Dec 1;30(12):1157-71. doi: 10.2165/11598470-000000000-00000. Erratum in: Pharmacoeconomics. 2015 Jun;33(6):611.

PMID:
23072659
6.

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis.

Wade DT, Collin C, Stott C, Duncombe P.

Mult Scler. 2010 Jun;16(6):707-14. doi: 10.1177/1352458510367462.

PMID:
20558502
7.

Advances in the management of multiple sclerosis spasticity: recent clinical trials.

Fernández O.

Eur Neurol. 2014;72 Suppl 1:9-11. doi: 10.1159/000367616.

PMID:
25278117
8.

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

Sastre-Garriga J, Vila C, Clissold S, Montalban X.

Expert Rev Neurother. 2011 May;11(5):627-37. doi: 10.1586/ern.11.47. Review.

PMID:
21456949
9.

Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.

García-Merino A.

Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):9-13. doi: 10.1586/ern.13.4. Review.

PMID:
23369054
10.

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.

Syed YY, McKeage K, Scott LJ.

Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Review.

PMID:
24671907
11.

[Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].

Wissel J, Entner T.

Wien Klin Wochenschr. 2001;113 Suppl 4:20-4. Review. German.

PMID:
15506048
12.
14.

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group..

J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1125-32. doi: 10.1136/jnnp-2012-302468.

PMID:
22791906
15.

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P; Sativex Spasticity Study Group..

Eur J Neurol. 2011 Sep;18(9):1122-31. doi: 10.1111/j.1468-1331.2010.03328.x.

PMID:
21362108
16.

Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.

Leocani L, Nuara A, Houdayer E, Schiavetti I, Del Carro U, Amadio S, Straffi L, Rossi P, Martinelli V, Vila C, Sormani MP, Comi G.

J Neurol. 2015 Nov;262(11):2520-7. doi: 10.1007/s00415-015-7878-1.

PMID:
26289497
17.

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).

Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R.

Mult Scler. 2012 Feb;18(2):219-28. doi: 10.1177/1352458511419700.

PMID:
21878454
18.

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.

Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group..

Eur J Neurol. 2007 Mar;14(3):290-6.

PMID:
17355549
19.

Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?

Wade D.

Expert Rev Neurother. 2012 Apr;12(4 Suppl):9-14. doi: 10.1586/ern.12.12. Review.

PMID:
22509986
20.

Medicinal cannabis extracts for the treatment of multiple sclerosis.

Smith PF.

Curr Opin Investig Drugs. 2004 Jul;5(7):727-30.

PMID:
15298068
Items per page

Supplemental Content

Support Center